Andere talen Alnylam Pharmaceuticals, Inc.

Aandelen

ALNY

US02043Q1076

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
150 ^USD	+4,18%		+2,66%	-21,66%

30/04	Medison Pharma en Alnylam Pharmaceuticals kondigen uitbreiding aan van hun multiregionale partnerschap in Europa en Israël om RNAi-therapeutica te commercialiseren in aanvullende Latam- en APAC-markten, waaronder Australië	CI
08/04	Sectorupdate: Gezondheidszorgaandelen maandag vlak tot hoger premarket	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	30/04
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	30/04
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18/04
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08/04
Sector Update: Health Care	08/04
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08/04
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session	20/03
Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	14/03
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	13/03
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY	12/03
ETF der Woche: Auf die Wende der Biotechs setzen	10/03
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	09/03
ETF de la semaine : miser sur le retournement des Biotechs	08/03
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03
Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen	06/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alnylam Pharmaceuticals, Inc.

Aandelen

ALNY

US02043Q1076

Andere talen

Filters